Browsing tag:

Gilead


Chemical entities SHINE in the top 10 fastest-growing drugs of 2016

This week, PharmaCompass continued its analysis of the top 10 fastest-growing drugs of 2016 by sales to evaluate the drugs that registered large sales growth. Please note that these are not the top-selling drugs, but are the top 10 drugs that registered the maximum growth in global sales over 2015. Interestingly, things didn’t appear that[…]

Read More

On December 6th, 2013 the FDA announced the approval of Gilead’s once-a-day pill Sofosbuvir, marketed as Sovaldi. The approval comes shortly after an FDA advisory committee awarded Gilead breakthrough therapy status for the once-a-day pill Sofosbuvir at the end of October 2013 (see previous Sofosbuvir article). The FDA committee also unanimously recommended the approval of[…]

Read More

The end of October 2013 saw a nod from the FDA given to Gilead’s New Drug Application for Sofosbuvir. As a greatly needed treatment for hepatitis C Sofosbuvir has proven to be effectual and tolerable in a number of studies. Sofosbuvir is marketed by Gilead Science, Inc. and is clearly set up for success in[…]

Read More

Patients suffering from debilitating pulmonary arterial hypertension, or PAH, find extensive relief when treated with ambrisentan. Also known as the brand name Letairis, marketed by Gilead, ambrisentan is effectual at preventing the thickening of the blood vessels, particularly those in the heart and lungs. Ambrisentan, CAS number 177036-94-1,  treats the high blood pressure in the[…]

Read More

Adefovir dipivoxil, CAS number 142340-99-6, is a nucleotide analog reverse transcriptase inhibitor, or “ntRTI”. Previously called bis-POM PMEA, adefovir dipivoxil is used is the treatment of chronic hepatitis B. Also produced under the trade names Hepsera and Preveon, adefovir dipivoxil is approved by the FDA for treatment in patients with active cases of chronic hepatitis[…]

Read More